Will the Supreme Court Grant Cert in Myriad Patent Case?
By Mari Serebrov
Thursday, February 16, 2012
WASHINGTON The Supreme Court is set to consider Friday whether it wants the last word on the patentability of Myriad Genetics Inc.'s claims on the BRCA1 and BRCA2 genes, used in diagnostics for breast and ovarian cancer.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.